__NUXT_JSONP__("/drugs/Lenvatinib", (function(a,b,c,d,e,f){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:b,conditionIndication:"In combination with everolimus for the treatment of unresectable advanced or metastatic renal cell carcinoma.",inn:c,marketingAuthorisationDate:"2016-08-25 00:00:00",marketingAuthorisationHolder:d,medicineName:"Kisplyx",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fkisplyx"},{activeSubstance:b,conditionIndication:"Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary\u002Ffollicular\u002FHürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.",inn:c,marketingAuthorisationDate:"2015-05-28 00:00:00",marketingAuthorisationHolder:d,medicineName:e,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Flenvima"}],fdaDrugLabel:[{brand:e,indication:"1 INDICATIONS AND USAGE LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer (DTC) For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma (RCC) In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma (HCC) For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) Endometrial Carcinoma (EC) In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.4 ) 1.1 Differentiated Thyroid Cancer LENVIMA is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). 1.2 Renal Cell Carcinoma LENVIMA, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). LENVIMA, in combination with everolimus, is indicated for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy. 1. 3 Hepatocellular Carcinoma LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). 1.4 Endometrial Carcinoma LENVIMA, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma (EC) that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",manufacturer:"Eisai Inc.",splSetId:"f4bedd21-efde-44c6-9d9c-b48b78d7ed1e"}],id:a,nciThesaurus:{casRegistry:"417716-92-8",chebiId:"",chemicalFormula:"C21H19ClN4O4",definition:"A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR\u002FFLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.",fdaUniiCode:"EE083865G2",identifier:"C95124",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C129825","C93259"],synonyms:["6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy-","E7080","ER-203492-00","LENVATINIB",a,"Multi-Kinase Inhibitor E7080"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FLenvatinib",extension:".json",createdAt:f,updatedAt:f}}],fetch:{},mutations:void 0}}("Lenvatinib","lenvatinib mesilate","lenvatinib","Eisai GmbH","Lenvima","2021-10-30T13:47:51.613Z")));